Jump to main content
Jump to site search

Issue 7, 2018
Previous Article Next Article

Synthesis of a novel HER2 targeted aza-BODIPY–antibody conjugate: synthesis, photophysical characterisation and in vitro evaluation

Author affiliations

Abstract

We herein report the synthesis and analysis of a novel aza-BODIPY–antibody conjugate, formed by controlled and regioselective bioconjugation methodology. Employing the clinically relevant antibody, which targets HER2 positive cancers, represents an excellent example of an antibody targeting strategy for this class of near-IR emitting fluorophore. The NIR fluorescence and binding properties were validated through in vitro studies using live cell confocal imaging.

Graphical abstract: Synthesis of a novel HER2 targeted aza-BODIPY–antibody conjugate: synthesis, photophysical characterisation and in vitro evaluation

Back to tab navigation

Supplementary files

Publication details

The article was received on 30 Nov 2017, accepted on 16 Jan 2018 and first published on 16 Jan 2018


Article type: Paper
DOI: 10.1039/C7OB02957H
Citation: Org. Biomol. Chem., 2018,16, 1144-1149
  •   Request permissions

    Synthesis of a novel HER2 targeted aza-BODIPY–antibody conjugate: synthesis, photophysical characterisation and in vitro evaluation

    Miffy. H. Y. Cheng, A. Maruani, H. Savoie, V. Chudasama and Ross. W. Boyle, Org. Biomol. Chem., 2018, 16, 1144
    DOI: 10.1039/C7OB02957H

Search articles by author

Spotlight

Advertisements